Global Information
회사소개 | 문의 | 비교리스트

성장호르몬 분비촉진 수용체(Type 1) : 파이프라인 리뷰

Growth Hormone Secretagogue Receptor Type 1 - Pipeline Review, H1 2020

리서치사 Global Markets Direct
발행일 2020년 04월 상품 코드 358687
페이지 정보 영문 85 Pages
가격
US $ 3,500 ₩ 4,193,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 7,000 ₩ 8,387,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 10,500 ₩ 12,581,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


성장호르몬 분비촉진 수용체(Type 1) : 파이프라인 리뷰 Growth Hormone Secretagogue Receptor Type 1 - Pipeline Review, H1 2020
발행일 : 2020년 04월 페이지 정보 : 영문 85 Pages

성장호르몬 분비촉진 수용체(GHSR)는 그렐린 수용체로도 알려져 있는 G단백질 공역 수용체이며, 그렐린을 결합합니다. 그렐린은 하수체에 의해 성장 호르몬을 분비시키는 수용체와의 결합에 의해 주변 기관으로부터 분비되는 식욕조절 인자입니다. 그렐린을 성장호르몬 분비촉진 수용체(GHSR1a)에 결합시켜 활성화하는 경로는 다양한 세포 조직 내에서 미토겐 활성화 단백질 키나아제, Akt, 산화질소 합성효소 및 AMPK 캐스케이드의 활성화를 관리하고 있습니다. 그렐린 수용체용 역작용제는 특히 비만 치료에서 주목받고 있습니다.

성장호르몬 분비촉진 수용체(Type 1) 치료제 개발 파이프라인 현황과 최신 업데이트에 의한 각 개발 단계 비교 분석, 기업 및 연구기관에 의해서 개발중인 치료제, 치료제 평가, 후기 단계 및 중지된 프로젝트, 최근의 뉴스와 발표 등의 정보를 전해드립니다.

서론

  • 조사 범위

개요

치료제 개발

  • 개발 단계별
  • 치료 영역별
  • 증상별

파이프라인 제품 개요

  • 후기 단계 제품
  • 초기 단계 제품

기업에서 개발중인 제품

대학/연구기관에서 개발중인 제품

치료제 평가

  • 단독치료 제품/병용 제품별
  • 작용기서별
  • 투여 경로별
  • 분자 종류별

치료제 개발에 참여하고 있는 기업

  • AstraZeneca Plc
  • Aeterna Zentaris Inc.
  • Asubio Pharma Co., Ltd.
  • Asubio Pharma Co., Ltd.
  • Alize Pharma SAS
  • Helsinn Healthcare S.A.
  • Pfizer Inc.
  • RaQualia Pharma Inc.
  • Rhythm Pharmaceuticals, Inc.

약제 프로파일

휴지중인 프로젝트

개발이 중지된 제품

주요 뉴스 및 프레스 릴리스

부록

도표

KSM 17.11.27

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

List of Tables

  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Therapy Areas, H1 2020
  • Number of Products under Development by Indication, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Number of Products under Investigation by Universities/Institutes, H1 2020
  • Products under Investigation by Universities/Institutes, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Pipeline by Aeterna Zentaris Inc, H1 2020
  • Pipeline by Allergan Plc, H1 2020
  • Pipeline by AstraZeneca Plc, H1 2020
  • Pipeline by Extend Biosciences Inc, H1 2020
  • Pipeline by Helsinn Group, H1 2020
  • Pipeline by Lumos Pharma Inc, H1 2020
  • Pipeline by Millendo Therapeutics Inc, H1 2020
  • Pipeline by Oxeia Biopharmaceuticals Inc, H1 2020
  • Pipeline by Pfizer Inc, H1 2020
  • Pipeline by RaQualia Pharma Inc, H1 2020
  • Pipeline by TheraSource LLC, H1 2020
  • Pipeline by Zeria Pharmaceutical Co Ltd, H1 2020
  • Dormant Products, H1 2020
  • Dormant Products, H1 2020 (Contd..1), H1 2020
  • Dormant Products, H1 2020 (Contd..2), H1 2020
  • Discontinued Products, H1 2020

List of Figures

  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Therapy Areas, H1 2020
  • Number of Products under Development by Top 10 Indications, H1 2020
  • Number of Products by Mechanism of Actions, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Top 10 Molecule Types, H1 2020

Summary:

Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Growth hormone secretagogue receptor (GHSR) also known as ghrelin receptor, is a G protein-coupled receptor that binds ghrelin. Ghrelin is an appetite-regulating factor secreted from peripheral organs via binding to the receptor resulting in the secretion of growth hormone by the pituitary gland. The pathway activated by binding of ghrelin to the growth hormone secretagogue receptor, GHSR1a, regulates the activation of the downstream mitogen-activated protein kinase, Akt, nitric oxide synthase, and AMPK cascades in different cellular systems. Inverse agonists for the ghrelin receptor could be particularly interesting for the treatment of obesity.

Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) pipeline Target constitutes close to 18 molecules. Out of which approximately 17 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 2, 3, 9 and 1 respectively.

Similarly, the universities portfolio in Phase II stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Toxicology, Cardiovascular, Genetic Disorders, Hormonal Disorders, Metabolic Disorders, Gastrointestinal, Genito Urinary System And Sex Hormones, Infectious Disease, Musculoskeletal Disorders and Women's Health which include indications Cancer Anorexia-Cachexia Syndrome, Growth Hormone Deficiency, Obesity, Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), Acute Ischemic Stroke, Alcohol Addiction, Born Small For Gestational Age (SGA), Cachexia, Chemotherapy Effects, Chronic Kidney Disease (Chronic Renal Failure), Diabetic Gastroparesis, Endocrine Gland Disorders, Fatigue, Ischemia, Prader-Willi Syndrome (PWS), Sepsis, Traumatic Brain Injury and Turner Syndrome.

The latest report Growth Hormone Secretagogue Receptor Type 1 - Pipeline Review, H1 2020, outlays comprehensive information on the Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR)
  • The report reviews Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) targeted therapeutics

Reasons to Buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Overview
  • Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Companies Involved in Therapeutics Development
  • Aeterna Zentaris Inc
  • Allergan Plc
  • AstraZeneca Plc
  • Extend Biosciences Inc
  • Helsinn Group
  • Lumos Pharma Inc
  • Millendo Therapeutics Inc
  • Oxeia Biopharmaceuticals Inc
  • Pfizer Inc
  • RaQualia Pharma Inc
  • TheraSource LLC
  • Zeria Pharmaceutical Co Ltd
  • Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Drug Profiles
  • anamorelin hydrochloride - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AZ-12861903 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • EXT-405 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • EXT-418 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • HM-03 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • HM-04 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ibutamoren mesylate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • livoletide - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • macimorelin acetate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • OXE-103 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Peptide to Agonize GHSR for Acute Ischemic Stroke, Acute Radiation Syndrome and Sepsis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PF-05190457 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • relamorelin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • RQ-00433412 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Antagonize Ghrelin Receptor for Obesity - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Agonize GHSR for Cachexia - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Synthetic Peptide to Modulate GHSR for Chronic Kidney Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Z-505 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Dormant Products
  • Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Discontinued Products
  • Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Product Development Milestones
  • Featured News & Press Releases
  • Apr 07, 2020: Aeterna Zentaris announces EMA decision to accept a modification to an agreed pediatric investigation plan for macimorelin
  • Apr 06, 2020: Millendo Therapeutics announces topline results for pivotal phase 2b study of Livoletide in patients with Prader-Willi Syndrome (PWS)
  • Apr 06, 2020: Aeterna Zentaris announces positive results in dose-finding pediatric study of macimorelin
  • Mar 12, 2020: Aeterna Zentaris announces settlement of previously disclosed class-action lawsuit
  • Feb 12, 2020: Aeterna Zentaris to present at Noble Capital Markets' 16th Annual Investor Conference
  • Jan 28, 2020: Aeterna Zentaris announces completion of patient recruitment in dose-finding pediatric study of Macimorelin
  • Dec 18, 2019: Aeterna Zentaris announces publication of GHD Management Guidelines
  • Nov 14, 2019: Millendo closes enrolment for first part of livoletide's ZEPHYR trial
  • Nov 07, 2019: Millendo Therapeutics to Host Prader-Willi Syndrome (PWS) Breakfast Symposium on Thursday, November 14, 2019
  • Sep 26, 2019: Millendo Therapeutics to present at Prader-Willi Syndrome Conferences
  • Aug 01, 2019: UAB and Children's of Alabama to investigate new treatment for patients with Prader-Willi syndrome
  • May 17, 2019: Allergan expands PLEDGE Clinical Research Program in Diabetic Gastroparesis
  • May 08, 2019: Millendo Therapeutics announces 21st European Congress of Endocrinology 2019 presentations on Livoletide for Prader-Willi syndrome
  • Mar 19, 2019: Millendo Therapeutics initiates pivotal Phase 2b/3 clinical study of livoletide for the treatment of Prader-Willi Syndrome
  • Mar 14, 2019: Millendo Therapeutics announces ENDO 2019 presentation on livoletide for Prader-Willi Syndrome
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
Back to Top
전화 문의
F A Q